faculty of physical therapy Cairo university
Dokki, Giza Governorate, Egypt
Location status: Recruiting
Location contact
Ali Ismail, lecturer
CONTACT
Ali MA Ismail, Lecturer
PRINCIPAL_INVESTIGATOR
Alshaymaa S Abd El-Azeim, lecturer
CONTACT
NCT Number: NCT06596109
honey is a natural functional food used in control cardiovascular risk factors but its effect on fatty liver is not investigated
Interested in participating?
Request Info30 year–50 year
All sexes
Interventional
Not applicable
Dokki, Giza Governorate, Egypt
Location status: Recruiting
Ali Ismail, lecturer
CONTACT
Ali MA Ismail, Lecturer
PRINCIPAL_INVESTIGATOR
Alshaymaa S Abd El-Azeim, lecturer
CONTACT
Forty fatty liver (non-alcoholic from) patients with obesity are included to be divided into group 1 who will contain 20 patients who will receive honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks. Group 2 who will contain 20 patients who will receive low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive natural unprocessed honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive low calorie diet and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
Time frame: it will be assessed after 12 weeks
it will be measured in serum
Time frame: it will be assessed after 12 weeks
it will be measured in serum
Time frame: it will be assessed after 12 weeks
it will be measured in serum
Time frame: it will be assessed after 12 weeks
it will be measured in serum
Time frame: it will be assessed after 12 weeks
it will be measured in serum
Time frame: it will be assessed after 12 weeks
it will be measured in serum
Time frame: it will be measured after 12 weeks
it will be measured in serum
Time frame: it will be measured after 12 weeks
it will be measured on empty stomach
Time frame: it will be measured after 12 weeks
it will be measured on empty stomach
Contact information is provided by the study sponsor or research team.
Ali MA Isamil, Lecturer
CONTACT
Alshaymaa S Abd El-Azeim, Lecturer
CONTACT
Cairo University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04899102
Behavior, Digestive System Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT06445361
Autoimmune Diseases, Diabetes Mellitus
Genk, Limburg, Belgium
View Trial DetailsNCT07068191
Alcohol-Induced Disorders, Alcohol-Related Disorders
Tyumen, Tyumen Oblast, Russia
View Trial DetailsNCT06503120
Diet, Healthy, Digestive System Diseases
Taichung, Taiwan
View Trial Details